Reactions 1704, p291 - 2 Jun 2018 Various toxicities: case report A 77-year-old woman developed hypertension, neutropenia, anaemia, urinary protein and loss of appetite while receiving chemotherapy with paclitaxel and ramucirumab [routes not stated]. The woman with gastric cancer had undergone distal gastrectomy and D2 dissection at the age of 76 years. Her histopathological results revealed mucinous carcinoma, HER2 negative, with progression of T4aN3H0P0CY0M0, stage IIIC for which she received adjuvant chemotherapy with gimeracil/ oteracil/tegafur [S-1] for one year. A year and four months after the surgery, recurrence of peritoneal metastases was noted. Therefore, she was started on secondary therapy with paclitaxel and ramucirumab. Before the therapy, her qualitative urinary protein was negative (-), serum creatinine was 0.49 mg/dL with creatinine clearance of 51 mL/min. She started receiving ramucirumab 8 mg/kg on days 1 and 15 along with paclitaxel 80 mg/m , which was administered on days 1, 8 and 15. The adverse events noted the first course were grade III hypertension, grade II neutropenia, anaemia, grade I urinary protein (qualitative 1+, random urinary protein/ Creatinine ratio of 0.75) and loss of appetite. The woman’s treatment with ramucirumab was discontinued due to urinary protein (qualitative 3+, urinary protein/Creatinine ratio of 3.78), but her paclitaxel was continued as monotherapy. Since there was urinary protein on th the 8 day (qualitative 2+, urinary protein/Creatinine ratio of 8.30), ramucirumab was not re-administered. From the third course onward urinary protein (qualitative (-) - (+), urinary protein/cr ratio 0.12 0.39) improved [not all outcomes stated]. Author comment: Ramucirumab (RAM) and paclitaxel (PTX) therapy is recommended as a secondary treatment for advanced recurrent gastric cancer; however, sufficient care is required for characteristic adverse events (AE). The adverse events observed in the first course were gr3 hypertension, gr2 neutropenia, anaemia, gr1 urinary protein (qualitative 1+, random urinary protein/Cr ratio 0.75), and loss of appetite. Kimura Y, et al. A Case of Recurrent Gastric Cancer with Grade 3 Proteinuria Caused by Ramucirumab plus Paclitaxel Therapy. Gan to Kagaku Ryoho 44: 1080-1082, No. 12, Nov 2017 [Japanese; summarised from a translation] - Japan 803322735 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera